FINNENCE ▪ THE WIRE FILE
THE WIRE · № 73653
SEC Filing■ Unclear/unknown
PANW filed 4 on 2026-10-09
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 discloses insider transactions but the filing text gives no direction or size.
Routine insider filing, no clear signal
CATALYST TO WATCH
Details of shares bought or sold
MAIN RISK
Insider selling could weigh on sentiment
FULL DISPATCH
PANW (CIK 0001682260) filed a 4 on 2026-10-09.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTPalo Alto Networks · PANW
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Shanghai Henlius Biotech2026-10-08 12:00 UTC
New Phase 3 trial: A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Shanghai Henlius Biotech2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo — Dermavon Holdings Limited2026-10-08 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo — Dermavon Holdings Limited2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes — Amgen2026-10-08 12:00 UTC
New Phase 3 trial: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes — Amgen2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) — PTC Therapeutics2026-10-08 12:00 UTC
Phase 3 results posted: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) — PTC Therapeutics2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems — Bayer2026-10-08 12:00 UTC
Phase 3 results posted: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems — Bayer2026-10-08 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Safety Study of Viaskin Peanut to Treat Peanut Allergy — DBV Technologies2026-10-08 12:00 UTC
Phase 3 results posted: Safety Study of Viaskin Peanut to Treat Peanut Allergy — DBV Technologies2026-10-08 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.